==============================
EXAM TITLE: WGUD116 Advanced Pharmacology OA Exam Questions |
100% Correct Answers with Detailed Rationales (2026/2027 Edition)
Graduate Nursing Advanced Pharmacology Objective Assessment
==============================
SECTION 1: Pharmacokinetics and Pharmacodynamics
Question 1
A 72-year-old patient with chronic kidney disease (CKD) stage 4 (eGFR 28 mL/min) is
prescribed metformin 1,000 mg twice daily for type 2 diabetes. Based on pharmacokinetic
principles, what is the primary concern with this prescription?
A. Metformin is primarily metabolized by the liver, and hepatic impairment increases toxicity risk
B. Metformin is renally excreted unchanged, and reduced GFR significantly increases the risk of
lactic acidosis
C. Metformin has a narrow therapeutic index, and dosing must be adjusted based on
therapeutic drug monitoring
D. Metformin undergoes extensive first-pass metabolism, and CKD reduces hepatic blood flow
Correct Answer: B
Rationale: Metformin is eliminated primarily by renal tubular secretion via organic cation
transporters and is excreted unchanged in the urine. In patients with CKD stage 4 (eGFR <30
mL/min), metformin accumulation significantly increases the risk of lactic acidosis, a rare but
life-threatening adverse effect. The FDA contraindicates metformin use when eGFR falls below
30 mL/min. Metformin is not metabolized by the liver (it is excreted unchanged), does not have
a narrow therapeutic index, and does not undergo significant first-pass metabolism. The
prescriber should consider alternative antihyperglycemic agents such as DPP-4 inhibitors (with
dose adjustment) or insulin.
------------------------------
Question 2
A 45-year-old patient is prescribed warfarin 5 mg daily for atrial fibrillation. The patient is also
taking phenytoin 300 mg daily for seizure control. After two weeks, the INR is 1.2
(subtherapeutic). What is the most likely pharmacokinetic explanation for this finding?
,A. Phenytoin inhibits CYP2C9, reducing warfarin metabolism and increasing its plasma
concentration
B. Phenytoin induces CYP1A2 and CYP2C9, increasing warfarin metabolism and decreasing its
plasma concentration
C. Phenytoin displaces warfarin from plasma protein binding sites, increasing free warfarin and
INR
D. Phenytoin competes with warfarin for renal tubular secretion, increasing warfarin elimination
Correct Answer: B
Rationale: Phenytoin is a potent inducer of multiple cytochrome P450 enzymes, including
CYP1A2 and CYP2C9, which are the primary enzymes responsible for metabolizing both
S-warfarin (CYP2C9) and R-warfarin (CYP1A2). Enzyme induction increases the metabolic
clearance of warfarin, leading to subtherapeutic INR values. Initially, phenytoin may transiently
inhibit CYP2C9 (due to its biphasic effect), but with chronic administration, induction
predominates. Phenytoin does not significantly displace warfarin from protein binding, nor does
it compete for renal tubular secretion. The prescriber should increase the warfarin dose or
consider switching to a direct oral anticoagulant (DOAC) that does not interact with phenytoin.
------------------------------
Question 3
A patient with heart failure is prescribed lisinopril 10 mg daily. The nurse practitioner
understands that the therapeutic effect of ACE inhibitors in heart failure is primarily mediated
through which pharmacodynamic mechanism?
A. Direct vasodilation of vascular smooth muscle via nitric oxide release
B. Inhibition of angiotensin-converting enzyme, reducing angiotensin II and aldosterone
production
C. Blockade of angiotensin II type 1 (AT1) receptors on vascular smooth muscle
D. Inhibition of renin secretion from the juxtaglomerular apparatus
Correct Answer: B
Rationale: ACE inhibitors (ACEIs) such as lisinopril exert their therapeutic effects in heart failure
primarily by inhibiting angiotensin-converting enzyme (ACE), which converts angiotensin I to
angiotensin II. This inhibition reduces angiotensin II-mediated vasoconstriction,
aldosterone-mediated sodium and water retention, and cardiac remodeling. ACE inhibition also
prevents the degradation of bradykinin, which contributes to vasodilation but also explains the
side effect of cough. Direct vasodilation via nitric oxide describes nitrates. AT1 receptor
blockade describes ARBs. Inhibition of renin secretion describes direct renin inhibitors such as
aliskiren.
,------------------------------
Question 4
A 68-year-old patient with cirrhosis is prescribed lorazepam 1 mg every 8 hours as needed for
anxiety. The nurse practitioner understands that this drug selection is appropriate based on
which pharmacokinetic principle?
A. Lorazepam undergoes extensive hepatic metabolism and is therefore safe in cirrhosis
B. Lorazepam is metabolized via glucuronidation, which is preserved in hepatic impairment
C. Lorazepam is primarily renally excreted and does not require hepatic metabolism
D. Lorazepam has a high extraction ratio and is unaffected by hepatic blood flow changes
Correct Answer: B
Rationale: Lorazepam is metabolized primarily via hepatic glucuronidation (UGT enzymes), a
phase II metabolic pathway that is relatively preserved in hepatic impairment compared to
phase I oxidation (CYP enzymes). In patients with cirrhosis, drugs metabolized by oxidation
(e.g., diazepam, chlordiazepoxide) have significantly prolonged half-lives and increased risk of
accumulation and sedation. Lorazepam, oxazepam, and temazepam are preferred
benzodiazepines in hepatic impairment because they rely on glucuronidation. Lorazepam does
undergo hepatic metabolism (not primarily renal excretion), and while it has a lower extraction
ratio than some benzodiazepines, the key principle is the preservation of glucuronidation in liver
disease.
------------------------------
Question 5
A patient is prescribed digoxin 0.25 mg daily for atrial fibrillation with rapid ventricular response.
The patient has a serum creatinine of 1.8 mg/dL and a body weight of 55 kg. Using the
Cockcroft-Gault equation, the patient's creatinine clearance is approximately 30 mL/min. What is
the most appropriate initial dosing adjustment?
A. Continue digoxin 0.25 mg daily; no adjustment is needed
B. Reduce the dose to 0.125 mg daily and monitor serum digoxin levels
C. Switch to amiodarone, as digoxin is contraindicated in renal impairment
D. Increase the dose to 0.375 mg daily to compensate for reduced renal clearance
Correct Answer: B
Rationale: Digoxin is primarily eliminated unchanged by the kidneys (approximately 60-80%). In
patients with reduced creatinine clearance (CrCl <50 mL/min), the maintenance dose must be
reduced to prevent toxicity. The standard maintenance dose of 0.125-0.25 mg daily should be
, reduced to 0.125 mg daily (or every other day) when CrCl is approximately 30 mL/min. Digoxin
has a narrow therapeutic index (0.5-2.0 ng/mL), and toxicity can cause life-threatening
arrhythmias, nausea, vomiting, and visual disturbances. Serum digoxin levels should be
monitored after steady state is achieved (approximately 5 half-lives, or 7-10 days in renal
impairment). Digoxin is not contraindicated in renal impairment but requires dose adjustment.
Amiodarone is an alternative but interacts with digoxin if used concurrently.
------------------------------
Question 6
A patient taking rifampin for tuberculosis develops a reduced therapeutic effect of oral
contraceptives. Which pharmacokinetic mechanism best explains this interaction?
A. Rifampin inhibits CYP3A4, reducing the metabolism of ethinyl estradiol
B. Rifampin induces CYP3A4 and P-glycoprotein, increasing the clearance of contraceptive
hormones
C. Rifampin displaces contraceptive hormones from plasma protein binding, increasing their
free fraction
D. Rifampin competes with contraceptive hormones for absorption in the gastrointestinal tract
Correct Answer: B
Rationale: Rifampin is one of the most potent inducers of cytochrome P450 enzymes,
particularly CYP3A4, and also induces P-glycoprotein (an efflux transporter). Combined oral
contraceptives containing ethinyl estradiol and progestins are metabolized by CYP3A4 and
transported by P-glycoprotein. Rifampin induction significantly increases the clearance of these
hormones, reducing their plasma concentrations and contraceptive efficacy. This interaction is
so well-established that rifampin is considered a contraindication to hormonal contraceptives,
and alternative contraceptive methods (e.g., non-hormonal or high-dose progestin-only
methods) must be used. Rifampin does not inhibit CYP3A4, displace hormones from protein
binding, or compete for GI absorption.
------------------------------
Question 7
A patient with hypertension is prescribed propranolol 40 mg twice daily. The nurse practitioner
understands that propranolol's efficacy in reducing blood pressure is primarily related to which
pharmacodynamic effect?
A. Selective blockade of beta-1 adrenergic receptors in the heart, reducing cardiac output
B. Non-selective blockade of beta-1 and beta-2 adrenergic receptors, reducing cardiac output
and renin release
EXAM TITLE: WGUD116 Advanced Pharmacology OA Exam Questions |
100% Correct Answers with Detailed Rationales (2026/2027 Edition)
Graduate Nursing Advanced Pharmacology Objective Assessment
==============================
SECTION 1: Pharmacokinetics and Pharmacodynamics
Question 1
A 72-year-old patient with chronic kidney disease (CKD) stage 4 (eGFR 28 mL/min) is
prescribed metformin 1,000 mg twice daily for type 2 diabetes. Based on pharmacokinetic
principles, what is the primary concern with this prescription?
A. Metformin is primarily metabolized by the liver, and hepatic impairment increases toxicity risk
B. Metformin is renally excreted unchanged, and reduced GFR significantly increases the risk of
lactic acidosis
C. Metformin has a narrow therapeutic index, and dosing must be adjusted based on
therapeutic drug monitoring
D. Metformin undergoes extensive first-pass metabolism, and CKD reduces hepatic blood flow
Correct Answer: B
Rationale: Metformin is eliminated primarily by renal tubular secretion via organic cation
transporters and is excreted unchanged in the urine. In patients with CKD stage 4 (eGFR <30
mL/min), metformin accumulation significantly increases the risk of lactic acidosis, a rare but
life-threatening adverse effect. The FDA contraindicates metformin use when eGFR falls below
30 mL/min. Metformin is not metabolized by the liver (it is excreted unchanged), does not have
a narrow therapeutic index, and does not undergo significant first-pass metabolism. The
prescriber should consider alternative antihyperglycemic agents such as DPP-4 inhibitors (with
dose adjustment) or insulin.
------------------------------
Question 2
A 45-year-old patient is prescribed warfarin 5 mg daily for atrial fibrillation. The patient is also
taking phenytoin 300 mg daily for seizure control. After two weeks, the INR is 1.2
(subtherapeutic). What is the most likely pharmacokinetic explanation for this finding?
,A. Phenytoin inhibits CYP2C9, reducing warfarin metabolism and increasing its plasma
concentration
B. Phenytoin induces CYP1A2 and CYP2C9, increasing warfarin metabolism and decreasing its
plasma concentration
C. Phenytoin displaces warfarin from plasma protein binding sites, increasing free warfarin and
INR
D. Phenytoin competes with warfarin for renal tubular secretion, increasing warfarin elimination
Correct Answer: B
Rationale: Phenytoin is a potent inducer of multiple cytochrome P450 enzymes, including
CYP1A2 and CYP2C9, which are the primary enzymes responsible for metabolizing both
S-warfarin (CYP2C9) and R-warfarin (CYP1A2). Enzyme induction increases the metabolic
clearance of warfarin, leading to subtherapeutic INR values. Initially, phenytoin may transiently
inhibit CYP2C9 (due to its biphasic effect), but with chronic administration, induction
predominates. Phenytoin does not significantly displace warfarin from protein binding, nor does
it compete for renal tubular secretion. The prescriber should increase the warfarin dose or
consider switching to a direct oral anticoagulant (DOAC) that does not interact with phenytoin.
------------------------------
Question 3
A patient with heart failure is prescribed lisinopril 10 mg daily. The nurse practitioner
understands that the therapeutic effect of ACE inhibitors in heart failure is primarily mediated
through which pharmacodynamic mechanism?
A. Direct vasodilation of vascular smooth muscle via nitric oxide release
B. Inhibition of angiotensin-converting enzyme, reducing angiotensin II and aldosterone
production
C. Blockade of angiotensin II type 1 (AT1) receptors on vascular smooth muscle
D. Inhibition of renin secretion from the juxtaglomerular apparatus
Correct Answer: B
Rationale: ACE inhibitors (ACEIs) such as lisinopril exert their therapeutic effects in heart failure
primarily by inhibiting angiotensin-converting enzyme (ACE), which converts angiotensin I to
angiotensin II. This inhibition reduces angiotensin II-mediated vasoconstriction,
aldosterone-mediated sodium and water retention, and cardiac remodeling. ACE inhibition also
prevents the degradation of bradykinin, which contributes to vasodilation but also explains the
side effect of cough. Direct vasodilation via nitric oxide describes nitrates. AT1 receptor
blockade describes ARBs. Inhibition of renin secretion describes direct renin inhibitors such as
aliskiren.
,------------------------------
Question 4
A 68-year-old patient with cirrhosis is prescribed lorazepam 1 mg every 8 hours as needed for
anxiety. The nurse practitioner understands that this drug selection is appropriate based on
which pharmacokinetic principle?
A. Lorazepam undergoes extensive hepatic metabolism and is therefore safe in cirrhosis
B. Lorazepam is metabolized via glucuronidation, which is preserved in hepatic impairment
C. Lorazepam is primarily renally excreted and does not require hepatic metabolism
D. Lorazepam has a high extraction ratio and is unaffected by hepatic blood flow changes
Correct Answer: B
Rationale: Lorazepam is metabolized primarily via hepatic glucuronidation (UGT enzymes), a
phase II metabolic pathway that is relatively preserved in hepatic impairment compared to
phase I oxidation (CYP enzymes). In patients with cirrhosis, drugs metabolized by oxidation
(e.g., diazepam, chlordiazepoxide) have significantly prolonged half-lives and increased risk of
accumulation and sedation. Lorazepam, oxazepam, and temazepam are preferred
benzodiazepines in hepatic impairment because they rely on glucuronidation. Lorazepam does
undergo hepatic metabolism (not primarily renal excretion), and while it has a lower extraction
ratio than some benzodiazepines, the key principle is the preservation of glucuronidation in liver
disease.
------------------------------
Question 5
A patient is prescribed digoxin 0.25 mg daily for atrial fibrillation with rapid ventricular response.
The patient has a serum creatinine of 1.8 mg/dL and a body weight of 55 kg. Using the
Cockcroft-Gault equation, the patient's creatinine clearance is approximately 30 mL/min. What is
the most appropriate initial dosing adjustment?
A. Continue digoxin 0.25 mg daily; no adjustment is needed
B. Reduce the dose to 0.125 mg daily and monitor serum digoxin levels
C. Switch to amiodarone, as digoxin is contraindicated in renal impairment
D. Increase the dose to 0.375 mg daily to compensate for reduced renal clearance
Correct Answer: B
Rationale: Digoxin is primarily eliminated unchanged by the kidneys (approximately 60-80%). In
patients with reduced creatinine clearance (CrCl <50 mL/min), the maintenance dose must be
reduced to prevent toxicity. The standard maintenance dose of 0.125-0.25 mg daily should be
, reduced to 0.125 mg daily (or every other day) when CrCl is approximately 30 mL/min. Digoxin
has a narrow therapeutic index (0.5-2.0 ng/mL), and toxicity can cause life-threatening
arrhythmias, nausea, vomiting, and visual disturbances. Serum digoxin levels should be
monitored after steady state is achieved (approximately 5 half-lives, or 7-10 days in renal
impairment). Digoxin is not contraindicated in renal impairment but requires dose adjustment.
Amiodarone is an alternative but interacts with digoxin if used concurrently.
------------------------------
Question 6
A patient taking rifampin for tuberculosis develops a reduced therapeutic effect of oral
contraceptives. Which pharmacokinetic mechanism best explains this interaction?
A. Rifampin inhibits CYP3A4, reducing the metabolism of ethinyl estradiol
B. Rifampin induces CYP3A4 and P-glycoprotein, increasing the clearance of contraceptive
hormones
C. Rifampin displaces contraceptive hormones from plasma protein binding, increasing their
free fraction
D. Rifampin competes with contraceptive hormones for absorption in the gastrointestinal tract
Correct Answer: B
Rationale: Rifampin is one of the most potent inducers of cytochrome P450 enzymes,
particularly CYP3A4, and also induces P-glycoprotein (an efflux transporter). Combined oral
contraceptives containing ethinyl estradiol and progestins are metabolized by CYP3A4 and
transported by P-glycoprotein. Rifampin induction significantly increases the clearance of these
hormones, reducing their plasma concentrations and contraceptive efficacy. This interaction is
so well-established that rifampin is considered a contraindication to hormonal contraceptives,
and alternative contraceptive methods (e.g., non-hormonal or high-dose progestin-only
methods) must be used. Rifampin does not inhibit CYP3A4, displace hormones from protein
binding, or compete for GI absorption.
------------------------------
Question 7
A patient with hypertension is prescribed propranolol 40 mg twice daily. The nurse practitioner
understands that propranolol's efficacy in reducing blood pressure is primarily related to which
pharmacodynamic effect?
A. Selective blockade of beta-1 adrenergic receptors in the heart, reducing cardiac output
B. Non-selective blockade of beta-1 and beta-2 adrenergic receptors, reducing cardiac output
and renin release
